Recognition and management of potential drug-drug interactions in patients on internal medicine wards

European Journal of Clinical Pharmacology

Volumn 63, Issue 11, 2007, Pages 1075-1083

  Vonbach, Priska ^a   Dubied, André ^a   Beer, Jürg H ^a   Krähenbühl, Stephan ^b  

^a Kantonsspital Baden   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adverse drug reaction; Drug drug interaction screening program; Drug drug interactions; Intervention; Medication error

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; POTASSIUM SALT; POTASSIUM SPARING DIURETIC AGENT;

ARTICLE; DRUG INFORMATION; DRUG INTERACTION SCREENING PROGRAM; DRUG SURVEILLANCE PROGRAM; HOSPITAL PATIENT; HUMAN; INTERNAL MEDICINE; MEDICATION ERROR; MORBIDITY; MORTALITY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG INTERACTIONS; FEEDBACK, PSYCHOLOGICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INPATIENTS; INTERNAL MEDICINE; INTERVENTION STUDIES; MALE; MIDDLE AGED; PATIENT DISCHARGE; PHARMACOEPIDEMIOLOGY; PHYSICIANS; PREVALENCE; QUALITY ASSURANCE, HEALTH CARE; SOFTWARE;

EID: 35248859762     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0359-4     Document Type: Article

References (41)

1. Einarson TR (1993) Drug-related hospital admissions. Ann Pharmacother 27(7-8):832-840
2. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274(1):29-34
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277(4):301-306
4. Lesar TS, Lomaestro BM, Pohl H (1997) Medication-prescribing errors in a teaching hospital. A 9-year experience. Arch Intern Med 157(14):1569-1576
5. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200-1205
6. Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ (2000) Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol 49(2):158-167
7. van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR (2000) Drug-related problems in hospitalised patients. Drug Saf 22(4):321-333
8. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15-19
9. Mjorndal T, Boman MD, Hagg S, Backstrom M, Wiholm BE, Wahlin A, Dahlqvist R (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 11(1):65-72
10. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW (2005) Adverse drug events occurring following hospital discharge. J Gen Intern Med 20(4):317-323
11. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S (2007) Drug-related problems in hospitals : a review of the recent literature. Drug Saf 30(5):379-407
12. van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH (2006) Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 29(2):161-168
13. Omar MA, Wilson JP (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36(2):288-295
14. Jankel CA, Fitterman LK (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9(1):51-59
15. Smith L, McGowan L, Moss-Barclay C, Wheater J, Knass D, Chrystyn H (1997) An investigation of hospital generated pharmaceutical care when patients are discharged home from hospital. Br J Clin Pharmacol 44(2):163-165
16. Himmel W, Tabache M, Kochen MM (1996) What happens to long-term medication when general practice patients are referred to hospital? Eur J Clin Pharmacol 50(4):253-257
17. Cook RI, Render M, Woods DD (2000) Gaps in the continuity of care and progress on patient safety. BMJ 320(7237):791-794
18. e-mediat. Pharmavista - information for healthcare professionals. Version February 2005 ed: e-mediat AG, Schönbühl, Switzerland 2005
19. Vonbach P, Dubied A, Krahenbuhl S, Beer JH (2005) Evaluation of drug interaction screening programs. Forum Med Suisse 8S(Suppl 23):P15
20. Stockley IH (2002) Stockley's drug interactions, 6th edn. The Pharmaceutical Press, London, Chicago
21. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, Cowper PA, Landsman PB, Cohen HJ, Feussner JR (1996) A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 100(4):428-437
22. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW (1999) Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 282(3):267-270
23. Bond CA, Raehl CL, Franke T (2002) Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy 22(2):134-147
24. Dean B, Schachter M, Vincent C, Barber N (2002) Causes of prescribing errors in hospital inpatients: a prospective study. Lancet 359(9315):1373-1378
25. Wiltink EH (1998) Medication control in hospitals: a practical approach to the problem of drug-drug interactions. Pharm World Sci 20(4):173-177
26. Mannheimer B, Ulfvarson J, Eklof S, Bergqvist M, Andersen-Karlsson E, Pettersson H, von Bahr C (2006) Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol 62(12):1075-1081
27. Chan AL (2005) Pharmacist intervention when interacting drugs are prescribed despite alerts. Am J Health Syst Pharm 62(17):1760-1763
28. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585-2590
29. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S (2005) Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28(3):263-275
30. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM (2003) Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 42(6):1253-1259
31. Buurma H, De Smet PA, Egberts AC (2006) Clinical risk management in Dutch community pharmacies : the case of drug-drug interactions. Drug Saf 29(8):723-732
32. Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163(12):1409-1416
33. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS (2003) Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 163(21):2625-2631
34. Payne TH, Nichol WP, Hoey P, Savarino J (2002) Characteristics and override rates of order checks in a practitioner order entry system. Proc AMIA Symp 602-606
35. Shah NR, Seger AC, Seger DL, Fiskio JM, Kuperman GJ, Blumenfeld B, Recklet EG, Bates DW, Gandhi TK (2006) Improving acceptance of computerized prescribing alerts in ambulatory care. J Am Med Inform Assoc 13(1):5-11
36. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, Brouwers JR (2005) Clinical relevance of drug-drug interactions : a structured assessment procedure. Drug Saf 28(12):1131-1139
37. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76(1):85-96
38. Hansten PD, Horn JR, Hazlet TK (2001) ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc 41(2):161-165
39. Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, Noskin GA (2004) The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med 164(7):785-792
40. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351(11):1089-1096
41. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) drug-drug interactions among elderly patients hospitalized for drug toxicity. Jama 289(13):1652-1658